A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease_ (MissionAD2)
Diseases of the Nervous System | Alzheimer's Disease
What is the purpose of this trial?
The name of this trial is MissionAD2. This 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with Early Alzheimer's Disease (EAD) including mild cognitive impairment (MCI) due to Alzheimer's Disease (AD)/Prodromal AD and the early stages of mild AD will be conducted to evaluate the efficacy and safety of elenbecestat (proposed international nonproprietary name [pINN]) (E2609).
- Ages50 - 85 years
- Trial withEisai Pharmaceuticals
- Start Date06/30/2018
- End Date08/30/2020
- Last Updated10/24/2018
- Study HIC#2000022087